ID   MM200
AC   CVCL_C836
SY   MM 200
DR   BTO; BTO:0005717
DR   cancercelllines; CVCL_C836
DR   Cosmic; 889014
DR   Cosmic; 928753
DR   GEO; GSM162935
DR   GEO; GSM219446
DR   Progenetix; CVCL_C836
DR   Wikidata; Q54906077
RX   PubMed=294576;
RX   PubMed=460945;
RX   PubMed=830403;
RX   PubMed=1697409;
RX   PubMed=3756862;
RX   PubMed=7520026;
RX   PubMed=8980186;
RX   PubMed=9354451;
RX   PubMed=9725211;
RX   PubMed=10070891;
RX   PubMed=15048078;
RX   PubMed=17363583;
RX   PubMed=17516929;
RX   PubMed=22383533;
RX   PubMed=23039341;
RX   PubMed=23455323;
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583; PubMed=22383533; PubMed=23455323).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Phe56Ile (c.166T>A); ClinVar=VCV000811083; Zygosity=Unspecified (PubMed=17363583).
CC   Omics: CNV analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Skin; UBERON=UBERON_0002097.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 05-10-23; Version: 22
//
RX   PubMed=294576; DOI=10.3109/00313027909059039;
RA   Muir P.D., Gunz F.W.;
RT   "A cytogenetic study of eight human melanoma cell lines.";
RL   Pathology 11:597-606(1979).
//
RX   PubMed=460945; DOI=10.3109/00313027909061945;
RA   Pope J.H., Morrison L.E., Moss D.J., Parsons P.G., Dunne R.M.;
RT   "Human malignant melanoma cell lines.";
RL   Pathology 11:191-195(1979).
//
RX   PubMed=830403;
RA   Goss P.D., Parsons P.G.;
RT   "The effect of hyperthermia and melphalan on survival of human
RT   fibroblast strains and melanoma cell lines.";
RL   Cancer Res. 37:152-156(1977).
//
RX   PubMed=1697409;
RA   Chenevix-Trench G., Martin N.G., Ellem K.A.O.;
RT   "Gene expression in melanoma cell lines and cultured melanocytes:
RT   correlation between levels of c-src-1, c-myc and p53.";
RL   Oncogene 5:1187-1193(1990).
//
RX   PubMed=3756862;
RA   Maynard K., Parsons P.G.;
RT   "Cross-sensitivity of methylating agents, hydroxyurea, and
RT   methotrexate in human tumor cells of the Mer- phenotype.";
RL   Cancer Res. 46:5009-5013(1986).
//
RX   PubMed=7520026; DOI=10.1002/ijc.2910580413;
RA   Hersey P., Si Z.-Y., Smith M.J., Thomas W.D.;
RT   "Expression of the co-stimulatory molecule B7 on melanoma cells.";
RL   Int. J. Cancer 58:527-532(1994).
//
RX   PubMed=8980186; DOI=10.1002/(SICI)1097-0215(19961211)68:6<795::AID-IJC18>3.0.CO;2-#;
RA   Thomas W.D., Smith M.J., Si Z.-Y., Hersey P.;
RT   "Expression of the co-stimulatory molecule CD40 on melanoma cells.";
RL   Int. J. Cancer 68:795-801(1996).
//
RX   PubMed=9354451;
RA   Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M.,
RA   Gabrielli B.G., Parsons P.G., Hayward N.K.;
RT   "CDKN2A/p16 is inactivated in most melanoma cell lines.";
RL   Cancer Res. 57:4868-4875(1997).
//
RX   PubMed=9725211; DOI=10.4049/jimmunol.161.5.2195;
RA   Thomas W.D., Hersey P.;
RT   "TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in
RT   Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of
RT   target cells.";
RL   J. Immunol. 161:2195-2200(1998).
//
RX   PubMed=10070891; DOI=10.1038/sj.bjc.6690147;
RA   Zerp S.F., van Elsas A., Peltenburg L.T.C., Schrier P.I.;
RT   "p53 mutations in human cutaneous melanoma correlate with sun exposure
RT   but are not always involved in melanomagenesis.";
RL   Br. J. Cancer 79:921-926(1999).
//
RX   PubMed=15048078; DOI=10.1038/sj.onc.1207563;
RA   Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M.,
RA   Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L.,
RA   Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G.,
RA   Meltzer P.S., Ringner M., Hayward N.K.;
RT   "Microarray expression profiling in melanoma reveals a BRAF mutation
RT   signature.";
RL   Oncogene 23:4060-4067(2004).
//
RX   PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152;
RA   Stark M.S., Hayward N.K.;
RT   "Genome-wide loss of heterozygosity and copy number analysis in
RT   melanoma using high-density single-nucleotide polymorphism arrays.";
RL   Cancer Res. 67:2632-2642(2007).
//
RX   PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x;
RA   Johansson P., Pavey S., Hayward N.K.;
RT   "Confirmation of a BRAF mutation-associated gene expression signature
RT   in melanoma.";
RL   Pigment Cell Res. 20:216-221(2007).
//
RX   PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676;
RA   Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V.,
RA   Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M.,
RA   Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.;
RT   "A high-throughput panel for identifying clinically relevant mutation
RT   profiles in melanoma.";
RL   Mol. Cancer Ther. 11:888-897(2012).
//
RX   PubMed=23039341; DOI=10.1186/1476-4598-11-75;
RA   Byron S.A., Loch D.C., Wellens C.L., Wortmann A., Wu J.-Y., Wang J.,
RA   Nomoto K., Pollock P.M.;
RT   "Sensitivity to the MEK inhibitor E6201 in melanoma cells is
RT   associated with mutant BRAF and wildtype PTEN status.";
RL   Mol. Cancer 11:75.1-75.15(2012).
//
RX   PubMed=23455323; DOI=10.1038/onc.2013.45;
RA   Becker T.M., Boyd S.C., Mijatov B., Gowrishankar K., Snoyman S.,
RA   Pupo G.M., Scolyer R.A., Mann G.J., Kefford R.F., Zhang X.D.,
RA   Rizos H.;
RT   "Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3
RT   transcription factor.";
RL   Oncogene 33:1158-1166(2014).
//